Pfizer is acquiring Array Biopharma for $10.64 billion in cash. Pfizer will pay $48 per share in cash to acquire Array. Ms. Sharp has been appointed to the Audit Committee of the Board. And Twin Peaks Liquor is...GET BREAKING NEWS IN YOUR BROWSER. The deal will give Pfizer access to Array's approved drugs for skin cancer and the targeted cancer medicines in its pipeline. The proposed acquisition of Array strengthens our innovative biopharmaceutical business, is expected to enhance its long-term growth trajectory, and sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer’s existing expertise in breast and prostate cancers.” The merger, subject to regulatory approvals, is expected to be completed later this year. Array's binimetinib is currently being developed for ovarian cancer and melanomas, but combinations provide for a long-lived pipeline. It sends a message to potential investors about the opportunities in bioscience beyond the coasts, particularly given the infrastructure for innovation and research supported by a talented workforce, and a positive business climate in Colorado, she said.The merger “is exciting news for Colorado,” said Jennifer Jones Paton, president and CEO of the Colorado Bioscience Association, a trade group that represents more than 700 bioscience companies in the state.Array CEO Ron Squarer in a statement said, “We are incredibly proud that Pfizer has recognized the value Array has brought to patients and our remarkable legacy discovering and advancing molecules with great potential to impact and extend the lives of patients in critical need. Array BioPharma Inc. (ARRY:NASDAQ) Array BioPharma Inc. (ARRY:NASDAQ) has a market of $565M. We’re excited our team will have access to world-class resources and a broader research platform to continue this critical work.”We love a good brew any time of the year, but summer is beer season! A free inside look at company reviews and salaries posted anonymously by employees.
Real time Array BioPharma (ARRY) stock price quote, stock graph, news & analysis. The merger agreement was announced Monday. There is a "cool kid" inner circle that gets what they want, and people outside that … Array BioPharma …
Array BioPharma Inc. (ARRY) F4Q2012 Earnings Conference Call August 14, 2012, 09:00 a.m. This firm is working on late-stage clinical programs with modest expectations. He...Want to make the best chicken and waffles you’ve ever had? From Covance CEO to short-lived LabCorp diagnostics lead, Ratliff lands at AMRI ... September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that … An ex-US At the time of writing our data says that Array BioPharma Inc. has a market cap of US$3.8b, and is paying total annual CEO compensation of US$5.6m. Tricia Haugeto - IR Ron Squarer - CEO Mike Carruthers - CFO